scholarly journals Corrigendum to ‘Disseminated mucormycosis in a paediatric patient: Lictheimia corymbifera successfully treated with combination antifungal therapy’ [Medical Mycology Case Reports (2014) 18–21]

2015 ◽  
Vol 10 ◽  
pp. 34
Author(s):  
Anita Campbell ◽  
Celia Cooper ◽  
Stephen Davis
Keyword(s):  
Paediatric Patient ◽  
Antifungal Therapy ◽  
Case Reports ◽  
Medical Mycology ◽  
Disseminated Mucormycosis

scholarly journals Assessment of Talaromyces Marneffei Infection of the Intestine in Three Patients and a Systematic Review of Case Reports

2020 ◽  
Vol 7 (6) ◽  
Author(s):  
Mianluan Pan ◽  
Jie Huang ◽  
Ye Qiu ◽  
Wen Zeng ◽  
Zhangcheng Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antifungal Therapy ◽  
Chinese Literature ◽  
Case Reports ◽  
Gastrointestinal Symptoms ◽  
Reticuloendothelial System ◽  
Intestinal Wall ◽  
Talaromyces Marneffei ◽  
Intestinal Infections ◽  
Stool Cultures

Abstract Background Hematogenous dissemination of Talaromyces marneffei can result in multiorgan involvement (skin, lung, and reticuloendothelial system involvement); however, few studies have reported intestinal T marneffei infections. We investigated clinical features, management, and patient outcomes concerning Talaromyces-related intestinal infections. Methods Patients with Talaromycosis between August 2012 and April 2019 at The First Affiliated Hospital of Guangxi Medical University, China, were retrospectively analyzed. Patients presenting with intestinal Talaromycosis and endoscopy-confirmed diagnoses were investigated. We also undertook a systematic review of the relevant English and Chinese literature. Results Of 175 patients diagnosed with Talaromycosis, 33 presented with gastrointestinal symptoms, and 31 underwent stool cultures, 1 of which tested positive. Three patients had gastrointestinal symptoms and negative stool cultures, and endoscopic tissue biopsy confirmed a pathological diagnosis. A systematic review of 14 reports on human Talaromycosis identified an additional 16 patients. Fever, weight loss, and anemia were the most common symptoms, along with abdominal pain, diarrhea, and bloody stools. Abdominal computed tomography showed intestinal wall edema and thickening and/or abdominal lymphadenopathy. Endoscopy showed erosion, hyperemia, edema, and multiple intestinal mucosal ulcers. Of the 19 patients, 16 received antifungal therapy, 14 of whom recovered and 2 died. Three patients received no therapy and died. Conclusions Gastrointestinal disseminated Talaromycosis is not rare and can affect the stomach, duodenum, and colon, and may involve the entire digestive tract. Colon is the most common site. Endoscopy is needed for patients presenting with gastrointestinal symptoms in T marneffei-infected endemic areas. Systemic application of effective antifungal therapy can improve the prognosis.

scholarly journals Subcutaneous Granulomatous Inflammation due to Basidiobolomycosis: Case Reports of 3 Patients in Buruli Ulcer Endemic Areas in Benin

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Luc V. C. Brun ◽  
Jean Jacques Roux ◽  
Ghislain E. Sopoh ◽  
Julia Aguiar ◽  
Miriam Eddyani ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Antifungal Therapy ◽  
Early Recognition ◽  
Case Reports ◽  
Buruli Ulcer ◽  
Granulomatous Inflammation ◽  
Giant Cells ◽  
Soft Tissue Tumors ◽  
Endemic Areas ◽  
Case Presentations

Background. Basidiobolomycosis is a rare subcutaneous mycosis, which can be mistaken for several other diseases, such as soft tissue tumors, lymphoma, or Buruli ulcer in the preulcerative stage. Microbiological confirmation by PCR for Basidiobolus ranarum and culture yield the most specific diagnosis, yet they are not widely available in endemic areas and with varying sensitivity. A combination of histopathological findings, namely, granulomatous inflammation with giant cells, septate hyphal fragments, and the Splendore-Hoeppli phenomenon, can confirm basidiobolomycosis in patients presenting with painless, hard induration of soft tissue. Case Presentations. We report on three patients misdiagnosed as suffering from Buruli ulcer, who did not respond to Buruli treatment. Histopathological review of the tissue sections from these patients suggests basidiobolomycosis. All patients had been lost to follow-up, and none received antifungal therapy. On visiting the patients at their homes, two were reported to have died of unknown causes. The third patient was found alive and well and had experienced local spontaneous healing. Conclusion. Basidiobolomycosis is a rare subcutaneous fungal disease mimicking preulcerative Buruli ulcer. We stress the importance of the early recognition by clinicians and pathologists of this treatable disease, so patients can timely receive antifungal therapy.

scholarly journals Disseminated and Relapsing Cryptococcosis: What We Still Have to Learn—a Case Series and Review of Literature

2021 ◽  
Author(s):  
Annarita Botta ◽  
Matteo Piccica ◽  
Filippo Lagi ◽  
Beatrice Borchi ◽  
Lorenzo Zammarchi ◽  
...  
Keyword(s):  
Antifungal Therapy ◽  
Case Reports ◽  
Case Series ◽  
Induction Phase ◽  
Immunosuppressed Patient ◽  
Limited Data ◽  
Therapeutic Approaches ◽  
Risk Factors For Recurrence ◽  
Resistant Strains

AbstractTwo cases of disseminated cryptococcosis are described. The first was an HIV-infected patient where cryptococcosis was diagnosed as “unmasking immune reconstitution syndrome”; the second was an immunosuppressed patient with multiple myeloma. In both cases, a definitive healing could not be reached despite long therapeutic approaches. This review summarizes both the most recent and relevant studies about disseminated and refractory form of cryptococcal infections and identifies research gaps. Given the limited data, we draw some conclusions with respect to management from literature: not clear and accepted indication are available regarding disseminated cryptococcosis, no specific schemes were identified, and the duration of therapy is usually decided case by case and supported only by case reports. In this perspective, usually standard therapeutic schemes and duration of induction depend on multiple factors (e.g., neurologic deficit, non-HIV/non transplant status, CSF culture positivity at 2 weeks, etc.). We found that there are no empiric and literature data that support a role of cryptococcal serum antigen (CRAG) in guiding the antifungal therapy; with the data collected, we think that although is possible, it is very rare to find disseminated cryptococcosis with negative CRAG. We looked also for the more important risk factor of recurrence. Some possible causes explored are risk of azole resistant strains, pre-existent conditions of patients that play a permissive role and the common situation where flucytosine is unavailable that led to suboptimal induction phase of therapy. Herein, we discuss disseminated cryptococcosis with a particular attention to antifungal therapy, role of cryptococcal antigen, and risk factors for recurrence of disease.

scholarly journals Eradication of Lomentospora prolificans Osteomyelitis of the Wrist with Combination Antifungal Therapy, Voriconazole Bone Cement, and Surgical Debridement

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jeremy Lee ◽  
Mark Wilson ◽  
Nikki Casey
Keyword(s):  
Bone Cement ◽  
Antifungal Therapy ◽  
Synergistic Effects ◽  
Case Reports ◽  
Source Control ◽  
Current Evidence ◽  
Causative Organism ◽  
Intrinsic Resistance ◽  
Clinical Benefits

Lomentospora prolificans is an emerging pathogen that is difficult to treat due to its intrinsic resistance to currently available antifungal agents. Current evidence demonstrates synergy between Azoles and Terbinafine against L. prolificans infections, while adjunct use of antifungal agent-loaded bone cement has also shown favourable outcomes. We report a case of an immunosuppressed adult with rheumatoid arthritis who developed L. prolificans osteomyelitis in his right wrist following trauma and subsequent exposure to commercially available fertiliser. The infection was successfully eradicated via a combination of aggressive, staged surgical source control, antifungal therapy using voriconazole and Terbinafine, and insertion of voriconazole-loaded bone cement into the wrist and carpus. The utility of this approach supports the synergistic effects of voriconazole and Terbinafine and, more broadly, the clinical benefits of antifungal-loaded bone cement, as demonstrated in previous case reports and in vitro studies. As such, combination antifungal therapy and voriconazole-loaded bone cement should be considered the therapy of choice in cases of osteomyelitis where L. prolificans is proven to be the causative organism.

scholarly journals <i>Candida</i> fracture-related infection: a systematic review

2021 ◽  
Vol 6 (7) ◽  
pp. 321-328
Author(s):  
Daniele De Meo ◽  
Gianluca Cera ◽  
Giancarlo Ceccarelli ◽  
Valerio Castagna ◽  
Raissa Aronica ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antifungal Therapy ◽  
Case Reports ◽  
Meta Analysis ◽  
Treatment Algorithm ◽  
Reoperation Rate ◽  
Diagnostic Challenge ◽  
Extensive Debridement ◽  
Initial Improvement ◽  
Systemic Antifungal Therapy

Abstract. Background: The aim of this study is to summarize and improve knowledge regarding a Candida fracture-related infection (CFRI) through a systematic review on the topic, accompanied by a case report. Methods: A systematic review and meta-analysis based on PRISMA statement were conducted on the CFRI topic. The following combined search terms were used to explore PubMed, Cochrane, and the Embase database: “fungal infection”, “candida”, “fracture related infection”, “bone infection”, “orthopedic infection”, “internal fixation”, “post-traumatic infection”, and “osteomyelitis”. Results: Out of 1514 records, only 5 case reports matched the selection criteria and were included. Moreover, a new case of CFRI, not previously described, was reported in this paper and reviewed. The main risk factors for CFRI were open wounds (three cases) and immunodeficiency (three cases). Initial improvement of clinical and laboratory signs of infection was noted in all cases. In the available short-term follow-up (mean 12.1 months; range 3–42), the reoperation rate was 33.3 %. Using a strategy based on extensive debridement/resection methods and prolonged systemic antifungal therapy (mean 8.8 weeks; range 6–18), four of six cases (66.6 %) were cured. Bone union occurred in three out of six cases. Conclusion: There is very low-quality evidence available regarding CFRI. Candida infections in surgically treated fractures are rare but difficult-to-treat events, with a slow onset, unspecific symptoms or signs, and a significant relapse risk; therefore, they still represent a current diagnostic challenge. The existing fracture-related infection treatment algorithm combined with long-term systemic antifungal therapy has an anecdotal value and needs more extensive studies to be validated.

Potential benefit of combination antifungal therapy in Aspergillus endocarditis

2020 ◽  
Vol 13 (6) ◽  
pp. e234008 ◽  
Author(s):  
Kate Lennard ◽  
Aiveen Bannan ◽  
Peter Grant ◽  
Jeffrey Post
Keyword(s):  
Aortic Valve ◽  
Antifungal Therapy ◽  
Case Reports ◽  
Single Agent ◽  
Survival Rates ◽  
Rare Condition ◽  
Prosthetic Aortic Valve ◽  
Single Agent Therapy

Aspergillus endocarditis (AE) is a rare condition with a mortality rate greater than 60%. While it is generally accepted that both antifungal therapy and surgery are necessary for survival, the optimal antifungal regimen is unclear. A 62-year-old man was diagnosed with AE of a prosthetic aortic valve, complicated by cerebral emboli. He underwent debridement of the aortic valve abscess and valve replacement, and was managed with a combination of liposomal amphotericin B and voriconazole for 7 weeks followed by long-term suppressive azole therapy. He remained well at follow-up 18 months later. Data from a review of case reports published between 1950 and 2010 revealed greater survival rates in patients managed with two or more antifungals as opposed to single agent therapy. We provide an updated literature review with similar findings, suggesting that dual agent antifungal therapy should be considered in patients with AE.

scholarly journals Mepolizumab -- therapeutic strategy for a paediatric patient with eosinophilic granulomatosis with polyangiitis

2022 ◽  
Author(s):  
Lota Ozola ◽  
Elīna Aleksejeva ◽  
Diāna Stoldere ◽  
Ineta Grantiņa ◽  
Zane Dāvidsone ◽  
...  
Keyword(s):  
Paediatric Patient ◽  
Granulomatosis With Polyangiitis ◽  
Case Reports ◽  
Small Vessel Vasculitis ◽  
Eosinophilic Granulomatosis With Polyangiitis ◽  
Multisystem Disorder ◽  
Paediatric Patients ◽  
Strauss Syndrome ◽  
Eosinophilic Granulomatosis ◽  
Churg Strauss

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from paediatric patients are limited. We present here a very rare practical EGPA clinical case involving a paediatric patient. Presently, data on mepolizumab usage in paediatric patients are limited, with only a few case reports published.

Sign in / Sign up

Export Citation Format

Share Document